Accelerate Diagnostics, Inc.

Equities

AXDX

US00430H2013

Advanced Medical Equipment & Technology

Delayed Nasdaq Other stock markets 03:20:23 2024-04-29 pm EDT			5-day change	1st Jan Change
0.9399 ^USD	+1.05%		+5.92%	-76.02%

Apr. 19	Certain Warrants of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 19-APR-2024.	CI
Apr. 19	Certain Restricted Stock Units of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 19-APR-2024.	CI

Accelerate Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 29, 2024 at 06:15 am EDT

Accelerate Diagnostics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 12.06 million compared to USD 12.75 million a year ago. Net loss was USD 61.62 million compared to USD 62.49 million a year ago.

Basic loss per share from continuing operations was USD 4.94 compared to USD 7.61 a year ago. Diluted loss per share from continuing operations was USD 4.94 compared to USD 7.61 a year ago.

Latest news about Accelerate Diagnostics, Inc.

Certain Warrants of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 19-APR-2024.	Apr. 18	CI
Certain Restricted Stock Units of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 19-APR-2024.	Apr. 18	CI
Certain Common Stock of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 19-APR-2024.	Apr. 18	CI
Certain Stock Options of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 19-APR-2024.	Apr. 18	CI
Accelerate Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Transcript : Accelerate Diagnostics, Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living Trust	Jan. 24	CI
Top Midday Decliners	Jan. 19	MT
Sector Update: Health Care Stocks Weaker Late Afternoon	Jan. 16	MT
Sector Update: Health Care	Jan. 16	MT
Top Midday Decliners	Jan. 16	MT
Accelerate Diagnostics, Inc. Announces Preliminary Unaudited Revenue Results for the Year Ended December 31, 2023	Jan. 07	CI
Accelerate Diagnostics Announces Collaboration for the Use of the Arc System in Combination With Bruker´s MALDI Biotyper	Nov. 27	CI
Accelerate Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : Accelerate Diagnostics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (AXDX) ACCELERATE DIAGNOSTICS Posts Q3 Revenue $3.3M	Nov. 09	MT
Transcript : Accelerate Diagnostics, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (AXDX) ACCELERATE DIAGNOSTICS Reports Q2 Revenue $2.9M	23-08-10	MT
Accelerate Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Accelerate Diagnostics to Conduct 1-for-10 Reverse Stock Split; Shares Fall	23-07-10	MT
Accelerate Diagnostics, Inc.(NasdaqCM:AXDX) dropped from Russell Microcap Growth Index	23-06-23	CI
Accelerate Diagnostics, Inc.(NasdaqCM:AXDX) dropped from Russell Microcap Index	23-06-23	CI
Accelerate Diagnostics, Inc.(NasdaqCM:AXDX) dropped from Russell 3000E Index	23-06-23	CI
Accelerate Diagnostics, Inc.(NasdaqCM:AXDX) dropped from Russell 3000E Growth Index	23-06-23	CI
Accelerate Diagnostics, Inc. announced that it expects to receive $10 million in funding from Chicago Venture Partners, L.P., PenderFund Capital Management Ltd., Wolverine Asset Management, LLC, RBC CMA LLC and other investor	23-06-08	CI

Chart Accelerate Diagnostics, Inc.

Duration

Period

More charts

Company Profile

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Accelerate Diagnostics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9301

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
ACCELERATE DIAGNOSTICS, INC.	-76.02%	20.15M
THERMO FISHER SCIENTIFIC	+8.40%	219B
DANAHER CORPORATION	+6.33%	183B
INTUITIVE SURGICAL, INC.	+10.70%	133B
BOSTON SCIENTIFIC CORPORATION	+24.94%	108B
SIEMENS HEALTHINEERS AG	+0.27%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+12.07%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.96%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.15%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+14.67%	39.35B

Other Advanced Medical Equipment & Technology